We are currently developing two product candidates: CEL – 01, for the treatment of Urinary Incontinence (UI) and CEL – 02, for the treatment of Fecal Incontinence (FI).
CEL-01 is a first generation, cell-based product intended for stress Urinary Incontinence (UI) treatment. CEL-01 has been evaluated in two phase II clinical trials with promising results.
CEL-02 is indicated for the treatment of Fecal Incontinence (FI); and is currently being evaluated in a phase II clinical trial.
The therapeutic cell therapy process
Celogos is a subsidiary of HRA Pharma, which focuses on cell-based technologies. The process involves isolating muscle cells or myoblasts from biopsies of a patient's muscle. These cells are then cultured, frozen, and re-injected into the patient. The myoblasts then develop into mature muscle cells, with the potential to repair the damaged tissue.